Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Neil Hapangama"'
Autor:
Swapan K. Chowdhury, Anima Ghosal, A.-D. Su, Shmuel Zbaida, Neil Hapangama, Yuan Yuan, Wei Tong
Publikováno v:
Drug Metabolism and Disposition. 34:628-635
Lonafarnib (Sarasar), a farnesyl transferase inhibitor, is currently under development for the treatment of solid tumors. Incubation of lonafarnib with human liver microsomes resulted in the formation of four oxidative metabolites (M1, M2, M3, and M4
Autor:
Swapan K. Chowdhury, Robert M. Iannucci, Kevin B. Alton, Neil Hapangama, Anima Ghosal, Yuan Yuan, James E. Patrick, Shmuel Zbaida, Joana Achanfuo-Yeboah
Publikováno v:
Drug Metabolism and Disposition. 32:314-320
Ezetimibe [1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone] (Zetia; Schering-Plough, Kenilworth, NJ) is the first in a new class of cholesterol-lowering agents known as cholesterol absorption inhib
Autor:
Anima Ghosal, Ragu Ramanathan, Neil Hapangama, Swapan K. Chowdhury, Yuan Yuan, Kevin B. Alton, Narendra S. Kishnani
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 35(12)
Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection. The objective of this study was to identify human liver cytochrome P450 enzyme(s) responsible for the m
Autor:
Swapan K. Chowdhury, Yuan Yuan, Ai Duen Iris Su, James E. Patrick, Neil Hapangama, N. Alvarez, Kevin B. Alton, Shmuel Zbaida, Anima Ghosal
Publikováno v:
Biopharmaceuticsdrug disposition. 25(6)
Desloratadine is a non-sedating antihistamine recently approved for the treatment of seasonal allergic rhinitis. The major metabolite of desloratadine in human plasma and urine is the glucuronide conjugate of 3-hydroxydesloratadine. 3-Hydroxydeslorat
Autor:
Shmuel Zbaida, Robert M. Iannucci, Kevin B. Alton, Joana Achanfuo-Yeboah, Anima Ghosal, James E. Patrick, Neil Hapangama, Yuan Yuan, Swapan K. Chowdhury
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 32(2)
Posaconazole (Noxafil, SCH 56592), an orally available broad-spectrum triazole antifungal, is currently in phase III clinical studies for treating serious opportunistic fungal infections. The major in vitro metabolite of posaconazole formed by human
Autor:
Xiaowen Lu, Debra Horne, James E. Patrick, Shmuel Zbaida, Anima Ghosal, Neil Hapangama, Yuan Yuan
Publikováno v:
Biopharmaceuticsdrug disposition. 24(9)
Cytochrome P450 (CYP) substrates that yield fluorescent metabolites were used for rapid screening of drug metabolism activities of 13 recombinant human cytochromes P450, human liver microsomes and human hepatocytes. Reproducible results were obtained
Autor:
Anima Ghosal, Neil Hapangama, Yuan Yuan, Xiaowen Lu, Debra Horne, James E. Patrick, Shmuel Zbaida
Publikováno v:
Biopharmaceutics & Drug Disposition; Dec2003, Vol. 24 Issue 9, p375-384, 10p
Autor:
Anima, Ghosal, Neil, Hapangama, Yuan, Yuan, Joana, Achanfuo-Yeboah, Robert, Iannucci, Swapan, Chowdhury, Kevin, Alton, E, Patrick James, Shmuel, Zbaida
Publikováno v:
Drug Metabolism and Disposition; March 2004, Vol. 32 Issue: 3 p314-20, 7p
Autor:
Anima, Ghosal, Neil, Hapangama, Yuan, Yuan, Joana, Achanfuo-Yeboah, Robert, Iannucci, Swapan, Chowdhury, Kevin, Alton, E, Patrick James, Shmuel, Zbaida
Publikováno v:
Drug Metabolism and Disposition; February 2004, Vol. 32 Issue: 2 p267-71, 5p